Derick Raal, Head of Lipidology and Endocrinology at Johannesburg Hospital, South Africa, stresses the importance of the PROMINENT trial in showing that triglyceride reduction with pemafibrate did not translate into better cardiovascular (CV) outcomes and looks forward to outcome studies of ANGPTL3 and apoCIII inhibition to establish their CV effects.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
